

Are women positive for the One Step but negative for the Two Step screening tests for gestational diabetes at higher risk for adverse outcomes?

CLAUDIA CAISSUTTI¹ , ADEEB KHALIFEH², GABRIELE SACCONI³  & VINCENZO BERGHELLA² 

¹Department of Experimental Clinical and Medical Science, DISM, Clinic of Obstetrics and Gynecology, University of Udine, Udine, Italy, ²Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA, and ³Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy

Key words

Diabetes, gestational diabetes mellitus, macrosomia, neonatal morbidity, neonatal mortality, pregnancy, screening

Correspondence

Vincenzo Berghella, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Thomas Jefferson University, 833 Chestnut, Philadelphia, PA 19107, USA.
E-mail: vincenzo.berghella@jefferson.edu

Conflict of interest

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Please cite this article as: Caissutti C, Khalifeh A, Saccone G, Berghella V. Are women positive for the One Step but negative for the Two Step screening tests for gestational diabetes at higher risk for adverse outcomes?. *Acta Obstet Gynecol Scand* 2018; 97:122–134.

Received: 1 August 2017

Accepted: 14 October 2017

DOI: 10.1111/aogs.13254

Abstract

Introduction. The aim of this study was to evaluate if women meeting criteria for gestational diabetes mellitus (GDM) by the One Step test as per International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria but not by other less strict criteria have adverse pregnancy outcomes compared with GDM-negative controls. The primary outcome was the incidence of macrosomia, defined as birthweight > 4000 g. **Material and methods.** Electronic databases were searched from their inception until May 2017. All studies identifying pregnant women negative at the Two Step test, but positive at the One Step test for IADPSG criteria were included. We excluded studies that randomized women to the One Step vs. the Two Step tests; studies that compared different criteria within the same screening method; randomized studies comparing treatments for GDM; and studies comparing incidence of GDM in women doing the One Step test vs. the Two Step test. **Results.** Eight retrospective cohort studies, including 29 983 women, were included. Five study groups and four control groups were identified. The heterogeneity between the studies was high. Gestational hypertension, preeclampsia and large for gestational age, as well as in some analyses cesarean delivery, macrosomia and preterm birth, were significantly more frequent, and small for gestational age in some analyses significantly less frequent, in women GDM-positive by the One Step, but not the Two Step. **Conclusion.** Women meeting criteria for GDM by IADPSG criteria but not by other less strict criteria have an increased risk of adverse pregnancy outcomes such as gestational hypertension, preeclampsia and large for gestational age, compared with GDM-negative controls. Based on these findings, and evidence from other studies that treatment decreases these adverse outcomes, we suggest screening for GDM using the One Step IADPSG criteria.

Abbreviations: ACOG, American College of Obstetrics and Gynecologists; C&C, Carpenter and Coustan; CDA, Canadian Diabetes Association; GCT, glucose challenge test; GDM, gestational diabetes mellitus; IADPSG, International Association of the Diabetes and Pregnancy Study Groups; LGA, large for gestational age; NICE, National Institute for Health and Care Excellence; NICU, neonatal intensive care unit; OGTT, oral glucose tolerance test; OR, odds ratio; RCT, randomized controlled trial; SGA, small for gestational age; WHO, World Health Organization.

Introduction

Gestational diabetes mellitus (GDM) is defined as impaired glucose tolerance first recognized during pregnancy (1). GDM affects about 7–20% of pregnant women and this value will probably increase in the future, due in particular to maternal obesity (2). Prompt diagnosis and correct treatment are essential, not only to decrease the risks of maternal and neonatal morbidity and mortality, but also to reduce health costs (1–6). In 2008, the hyperglycemia and adverse pregnancy outcomes (HAPO) study showed strong, continuous associations of maternal glucose levels below those diagnostic for diabetes with increased birthweight (7).

Concerning diagnostic criteria, during the last decades methods and cut-off values have changed several times and complete international consensus about which criteria to adopt has not been reached (1–6). The two most common approaches to screen pregnant women for GDM are the One Step and Two Step tests. Currently, the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) (2), the World Health Organization (WHO) (3), the International Federation of Obstetricians and Gynecologists (4), the Canadian Diabetes Association (CDA) (5) all recommend the 75 g 2 h One Step test, while The American College of Obstetricians and Gynecologists (ACOG) recommends the Two Step approach, with first a 50-g 1-h test, and then, for those with abnormal results, a 100-g 3-h test (6).

The One Step test usually diagnoses more women with GDM than the Two Step test (8). It is unclear if these ‘extra’ women diagnosed with GDM by the One Step test using IADPSG criteria but not by the Two Step test are at increased risks for GDM complications compared with women without GDM, and also, if they are, if treatment for this ‘mild’ GDM is beneficial.

Our objective was to evaluate mainly if women meeting criteria for GDM by IADPSG criteria, but not by other less strict criteria, have adverse pregnancy outcomes compared with GDM negative controls, and also if treatment of these women has any potential maternal or perinatal effects.

Material and methods

This is a review of the literature aimed at comparing maternal and neonatal outcomes of women meeting criteria for GDM by IADPSG criteria but not by other less strict criteria, vs. GDM-negative controls. All studies were identified through a review of the literature using PubMed, Ovid, Google Scholar and Cochrane Review. Databases were searched from their inception until May 2017. Search terms used were the following text words: “diabetes”, “trial”, “screening”, “diagnosis”, “one-step”,

“two-step”, “guidelines”, “review”, “randomized” and “clinical trial”. No restrictions for language or geographic location were applied. In addition, the reference lists of all identified articles were examined to identify studies not captured by electronic searches. The electronic search and the eligibility of the studies were independently assessed by two authors (GS, CC). Differences were discussed with a third reviewer (VB).

We sought to identify in particular studies including women meeting criteria for GDM based on the One Step test by IADPSG criteria but not by other less strict criteria, and reporting their outcomes compared with GDM-negative controls. We also looked for any information regarding GDM treatment of these (IADPSG-positive only) women, to compare outcomes between those treated vs. those untreated.

We included studies, of any design, identifying pregnant women positive for IADPSG criteria, but negative at the Two Step test as per ACOG Carpenter and Coustan (C&C) criteria (6), WHO 1999 criteria (9), CDA criteria (5), or National Institute for Health and Care Excellence (NICE) Two Step criteria (Table 1) (10). We excluded studies that randomized women to the One Step vs. the Two Step tests; studies that compared different criteria within the same screening method; randomized studies comparing treatments for GDM; studies comparing mainly incidence of GDM in women doing the One Step test vs. other women doing the Two Step test; and studies not reporting clinical outcomes.

Different criteria for GDM are shown in the Supplementary material (Table S1).

We defined different groups of women within these studies (Table 2). We defined the five study groups, all positive for IADPSG criteria, but negative for other less stringent GDM screening tests, as: (1) women who had at least one positive value on the 2-h 75-g oral glucose tolerance test (OGTT) according to IADPSG criteria, but were negative by C&C at the 100-g OGTT test (75-g IADPSG-positive; 100-g C&C-negative); (2) women who had at least one positive value on the 2-h 75-g OGTT according to IADPSG criteria, but were negative by WHO criteria (75-g IADPSG-positive; WHO-negative); (3) women who had at least one positive value on the 2-h 75-g OGTT

Key message

Women meeting criteria for gestational diabetes mellitus by One Step IADPSG criteria, but not by other less strict criteria, have an increased risk of adverse pregnancy outcomes compared with gestational diabetes mellitus-negative controls.

Table 1. Selected studies reporting outcomes of women meeting criteria for gestational diabetes mellitus based on the One Step test but not on the Two Step test.

| Author, year (origin) (Ref) | Study design | One Step positive criteria (Study group) | Control group | Two Step screening criteria | Primary outcome |
|-----------------------------------|-------------------------|---|---|--|---|
| Lapolla, 2011 (Italy) (14) | Retrospective cohort | 100-g IADPSG positive; C&C negative (Fasting 92–94 mg/ dL; 2 h 153– 154 mg/dL; <u>not treated</u>) [n = 112] | IADPSG negative (Fasting <92 mg/dL; 1 h < 180 mg/dL; 2 h < 153 mg/dL) [n = 1815] | 50-g 1 h; if >140 mg/dL: 100-g 3 h GTT 2 abnormal of: Fasting ≥95 mg/dL, or 1 h 180 mg/dL; 2 h 155 mg/dL; 3 h 140 mg/dL ^a | Perinatal outcomes |
| Bodmer-Roy, 2012 (Canada) (15) | Retrospective cohort | 75-g IADPSG positive; CDA negative (Fasting 92–95 mg/ dL; 1 h 180–190 mg/dL; 2 h 153– 159 mg/dL; <u>not treated</u>) [n = 186] | GCT-negative (50-g 1 h < 137 mg/dL) [n = 186] or IADPSG-negative (Fasting <92 mg/dL; 1 h < 180 mg/dL; 2 h < 153 mg/dL) [n = 186] | 50-g 1 h; if 137–184 mg/ dL: 75-g 2 h GTT One abnormal of: fasting ≥ 96 mg/dL; 1 h: ≥ 191 mg/dL; 2 h ≥ 160 mg/dL ^a | LGA >90th percentile |
| Benhalima, 2013 (Belgium) (16) | Retrospective cohort | 100-g IADPSG positive; C&C negative (Fasting 92–94 mg/ dL; 2 h 153– 154 mg/dL; <u>not treated</u>) [n = 160] | GCT-negative (50-g 1 h < 140 mg/dL) and IADPSG-negative (Fasting <92 mg/dL; 1 h < 180 mg/dL; 2 h < 153 mg/dL) [n = 6345] | 50 g 1 h; if ≥140 mg/dL: 100 g 3 h GTT 2 abnormal of: Fasting ≥95 mg/dL, or 1 h 180 mg/dL; 2 h 155 mg/dL; 3 h 140 mg/dL ^a | Pregnancy outcomes |
| Ethridge, 2014 (USA) (17) | Retrospective cohort | 100-g IADPSG positive; C&C negative (Fasting 92–94 mg/ dL; 2 h 153– 154 mg/dL; <u>not treated</u>) [n = 281] | GCT-negative (50-g 1 h < 135 mg/dL) [n = 6999] or IADPSG-negative (Fasting <92 mg/dL; 1 h < 180 mg/dL; 2 h < 153 mg/dL) [n = 772] | 50-g 1 h; if ≥135 mg/dL: 100-g 3 h GTT 2 abnormal of: Fasting ≥95 mg/dL, or 1 h 180 mg/dL; 2 h 155 mg/dL; 3 h 140 mg/dL ^a | Birthweight and neonatal outcomes |
| Liao, 2014 (China) (18) | Retrospective cohort | 100-g IADPSG positive; C&C negative (Fasting 92–94 mg/ dL; 2 h 153– 154 mg/dL; <u>not treated</u>) [n = 1314] | GCT-negative (50-g 1 h < 140 mg/dL) and IADPSG-negative (Fasting <92 mg/dL; 1 h < 180 mg/dL; 2 h < 153 mg/dL) [n = 2662] | 50 g 1 h; if ≥140 mg/dL: 100-g 3 h GTT 2 abnormal of: Fasting ≥95 mg/dL, or 1 h 180 mg/dL; 2 h 155 mg/dL; 3 h 140 mg/dL | Maternal and neonatal outcomes |
| Mayo, 2015 (Canada) (19) | Retrospective cohort | 75-g IADPSG positive; CDA negative (Fasting 92–95 mg/ dL; 1 h 180–190 mg/dL; 2 h 153– 159 mg/dL; <u>not treated</u>) [n = 155] | GCT-negative (50-g 1 h < 140 mg/dL) [n = 4183] or IADPSG negative (Fasting <92 mg/dL; 1 h < 180 mg/dL; 2 h < 153 mg/dL) [n = 526] | 50-g 1 h; if 140–184 mg/dL: 75-g 2 h GTT One abnormal of: fasting ≥95 mg/dL; 1 h: ≥191 mg/dL; 2 h ≥ 160 mg/dL ^a | Not stated |

Table 1. Continued

| Author, year (origin) (Ref) | Study design | One Step positive criteria (Study group) | Control group | Two Step screening criteria | Primary outcome |
|--------------------------------|----------------------|---|--|--|--------------------------------------|
| Meek, 2015 (UK) (20) | Retrospective cohort | 75-g IADPSG positive; NICE negative (Fasting 92–101 mg/ dL, 1 h \geq 153 mg/ dL; <u>not treated</u>) [n = 387] | IADPSG negative (Fasting <92 mg/dL; 1 h < 180 mg/dL; 2 h < 153 mg/dL) [n = 2406] | 50-g 1 h; if >138 mg/dL: 75-g 2 h GTT One abnormal of: fasting \geq 110/128 mg/dL; 2 h \geq 140 mg/dL ^b | Delivery and neonatal outcomes |
| Tward, 2016 (Canada) (21) | Retrospective cohort | 75-g IADPSG positive; CDA negative (Fasting 92–95 mg/ dL; 1 h 180– 190 mg/dL; 2 h 153 –159 mg/dL; <u>not treated</u>) [n = 99] | GCT-negative (50-g 1 h < 140 mg/dL [n = 1021] or IADPSG negative (Fasting <92 mg/dL; 1 h < 180 mg/dL; 2 h < 153 mg/dL) [n = 184] | 50-g 1 h; if >140 mg/dL: 75-g 2 h GTT 2 abnormal of: fasting \geq 95 mg/dL; 1 h: \geq 191 mg/dL; 2 h \geq 160 mg/dL | Fetal grown in twins |

CDA, Canadian Diabetes Association; C&C, Carpenter and Coustan criteria; GCT, glucose challenge test; GTT, glucose tolerance test; IADPSG, International Association of Diabetes Pregnancy Study Group; LGA, large for gestational age; NICE, National Institute for Health and Care Excellence; WHO, World Health Organization.

^a2008 Canadian Diabetes Association criteria (5).

^bWHO 1999 criteria until 2007 (fasting 148 mg/dL), than modified WHO 1999 (fasting 130 mg/dL).

according to IADPSG criteria, but were negative by CDA criteria (75-g IADPSG-positive; CDA-negative); (4) women who had at least one positive value on the 2-h 75-g OGTT according to IADPSG criteria, but were negative by NICE criteria (75-g IADPSG-positive; NICE-negative); (5) women who had at least one positive value on the 100-g OGTT according to IADPSG criteria, but were negative by C&C criteria at the 100-g OGTT test (100-g IADPSG-positive; C&C-negative).

We defined the four control groups as: (1) women with negative 50-g 1-h glucose challenge test results (GCT-negative); (2) women GDM-negative by IADPSG criteria on the 75-g One Step test (IADPSG-negative); (3) either (1) or (2), together (GCT-negative or IADPSG-negative); (4) women negative according to WHO criteria (WHO-negative).

We carefully extracted data from all selected papers and we resolved disagreements by discussion.

We planned to compare maternal and neonatal outcomes in study group (1) vs. any controls; study group (2) vs. any controls; study group (3) vs. any controls; study group (4) vs. any controls; study group (5) vs. any controls.

Among the five groups described above, we aimed to compare several outcomes. We identified as our primary outcome the incidence of macrosomia (defined as birthweight \geq 4000 g).

Secondary outcomes were the following maternal and neonatal outcomes: large-for-gestational-age (LGA) (birthweight > 90th centile), cesarean delivery, shoulder dystocia, maternal gestational hypertension (i.e. blood pressure \geq 140/90 mmHg occurring during pregnancy in previous

normotensive women), preeclampsia, admission to a neonatal intensive care unit (NICU admission), premature delivery (defined as delivery before 37 weeks of gestation), small-for-gestational-age (SGA) (birthweight < 90th centile), clinical neonatal hypoglycemia, live births and stillbirths.

The data analysis was completed independently by two authors (CC, GS) using REVIEW MANAGER v. 5.3 (The Nordic Cochrane Center, Cochrane Collaboration, 2014, Copenhagen, Denmark). The completed analyses were then compared, and any difference was resolved by discussion with a third reviewer (VB).

Data from each eligible study were extracted without modification of original data onto custom-made data collection forms. For continuous outcomes means \pm standard deviation were extracted and imported into REVIEW MANAGER v. 5.3.

Meta-analysis was performed using the random effects model of DerSimonian and Laird, to produce summary treatment effects in terms of mean difference or odds ratio (OR) with 95% confidence interval (95% CI). Heterogeneity was measured using I-squared (Higgins I²).

Before data extraction, the review was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42017065654).

Results

We identified 73 studies on GDM screening comparison, and these were assessed for eligibility (Figure 1). Sixty-two

Table 2. Study groups and Control groups definitions^a.

| Study groups (Ref) | Control groups |
|--|---|
| 1) 75-g IADPSG-positive; 100 g C&C-negative: no studies | 1) GCT-negative: 2 studies (16,18) |
| 2) 75-g IADPSG-positive; WHO-negative: no studies | 2) IADPSG-negative: 2 studies (14,20) |
| 3) 75-g IADPSG-positive; CDA-negative: 3 studies (15,19,21) | 3) GCT-negative or IADPSG-negative: 4 studies (15,17,19,21) |
| 4) 75-g IADPSG-positive; NICE-negative: 1 study (20) | 4) WHO-negative: no studies |
| 5) 100-g IADPSG-positive; C&C-negative: 4 studies (14,16–18) | |

CDA, Canadian Diabetes Association; C&C, Carpenter and Coustan criteria; GCT, glucose challenge test; IADPSG, International Association of Diabetes Pregnancy Study Group; NICE, National Institute for Health and Care Excellence; WHO, World Health Organization.

^aFor details of criteria, see Supplementary material (Table S1).

were excluded, and therefore 11 studies reporting outcomes of women meeting criteria for GDM based on the One Step test but not on the Two Step test were included. Deerochnawong et al. (11) and Mello et al. (12) were excluded because while women were given both tests (75 g and 100 g), the studies do not compare outcomes. O'Sullivan et al. (13) was excluded because the study and control groups contained overlapping patients. Therefore, finally, eight studies (14–21) were included for final analysis.

We found no study that compared 75-g IADPSG-positive, 100-g C&C-negative women to any of the possible controls. We found no study that compared 75-g IADPSG-positive, WHO-negative women to any of the possible controls, as O'Sullivan et al. (13) had to be excluded. Instead we recognized eight studies that identified women negative at the 75-g CDA, 75-g NICE test, or 100-g C&C tests, but positive for milder GDM criteria (either 75-g or 100-g IADPSG criteria) (14–21).

Three of the included studies considered women positive at 75-g IADPSG criteria, but CDA criteria negative (15,19,21). One study included women meeting criteria for GDM based on 75-g IADPSG criteria, but NICE criteria negative (20). Four of the included studies had as study group women positive for 100-g IADPSG criteria, but negative on C&C criteria (14,16–18).

Regarding control groups, two of the included studies considered women with negative GCT, six studies included as controls women who were IADPSG-negative, four studies considered GCT-negative or IADPSG-negative, and no studies had as control group women who were WHO-negative (Table 2).

Supplementary material (Table S1) reports the recommendations of guidelines used in the eight studies that we included in our analysis. Table 1 shows the characteristics of the included studies. All eight studies were retrospective cohort studies. For the GCT-negative controls, the cut-offs varied between 135 and 140 mg/dL. The study by Tward et al. includes only twin pregnancies, so

fetal outcomes are referred to both twins. No study treated for GDM either the study or control groups.

In the three studies of women positive at 75-g IADPSG criteria, but CDA criteria negative, gestational hypertension [17/341 (5.0%) vs. 112/5081 (2.2%); OR 2.55, 95% CI 1.41–4.61], preeclampsia [16/341 (4.7%) vs. 46/5081 (0.9%); OR 2.75, 95% CI 1.38–5.45], hypertensive complications [27/254 (10.6%) vs. 278/5914 (4.7%); OR 1.81, 95% CI 1.19–2.76], cesarean delivery [205/440 (46.6%) vs. 2180/6286 (34.7%); OR 1.68, 95% CI 1.34–2.11] and LGA babies [38/341 (11.1%) vs. 411/5081 (8.1%); OR 1.69, 95% CI 1.15–2.48] were significantly more common; our main outcome, macrosomia, was more frequent in women positive at 75-g IADPSG criteria and CDA criteria negative, but did not reach a statistically significant difference [39/341 (11.4%) vs. 475/5081 (9.3%); OR 1.32, 95% CI 0.90–1.92] (Tables 3 and 4).

In the one study of women positive on 75-g IADPSG criteria, but NICE criteria negative, macrosomia [112/387 (28.9%) vs. 403/2406 (16.8%); OR 2.02, 95% CI 1.59–2.58], LGA babies [115/387 (29.7%) vs. 406/2406 (16.9%); OR 2.08, 95% CI 1.63–2.65] and preeclampsia [39/387 (10.1%) vs. 174/2406 (7.2%); OR 1.44, 95% CI 1.00–2.07], were significantly more common. Other outcomes did not reach a statistically significant difference (Table 5 and 6).

In the four studies of women positive for 100-g IADPSG criteria, but negative on C&C criteria, preeclampsia [27/1474 (1.8%) vs. 66/9011 (0.7%); OR 1.82, 95% CI 1.09–3.05], gestational hypertension [75/1867 (4.0%) vs. 825/1859 (4.4%); OR 1.58, 95% CI 1.21–2.07], cesarean delivery [180/553 (32.5%) vs. 3860/15931 (24.2%); OR 1.46, 95% CI 1.21–1.75], LGA babies [157/1867 (8.4%) vs. 1688/18597 (9.1%); OR 1.36, 95% CI 1.13–1.64], preterm birth [113/1474 (7.7%) vs. 1799/9011 (20.0%); OR 1.67, 95% CI 1.33–2.10], NICU admission [116/1755 (6.6%) vs. 1318/16782 (7.9%); OR 1.32, 95% CI 1.06–1.64], and neonatal hypoglycemia [18/1314 (1.3%) vs. 18/2666 (0.7%); OR 2.04, 95% CI 1.06–3.94] were significantly more common; whereas SGA babies [13/243 (5.3%) vs.




Figure 1. Flow diagram of studies identified in the systematic review.

Table 3. Comparing of maternal outcomes between women who were 75-g IADPSG-positive, CDA-negative (Group 3 in Table 2); vs. any controls.

| Author, year (origin) (Ref) | Gestational hypertension | Preeclampsia | Hypertensive complications ^b | Shoulder dystocia | Cesarean delivery |
|---|-----------------------------------|----------------------------------|---|----------------------------------|---------------------------------------|
| Bodmer-Roy, 2012 (Canada) (15) | 8/186 (4.3%) vs. 7/372 (1.9%) | 12/186 (6.5%) vs. 10/372 (2.7%) | NR | 2/186 (1.1%) vs. 6/372 (1.6%) | 69/186 (37.1%) vs. 94/372 (25.3%) |
| Mayo, 2015 (Canada) (19) | 9/155 (5.8%) vs. 105/4709 (2.2%) | 4/155 (2.6%) vs. 36/4709 (0.8%) | 13/155 (8.4%) vs. 140/4709 (3.0%) | 3/155 (1.9%) vs. 88/4709 (1.9%) | 57/155 (36.8%) vs. 1247/4709 (26.5%) |
| Tward, 2016 (Canada) ^a (21), Total | NR | NR | 14/99 (14.1%) vs. 138/1205 (11.4%) | NR | 79/99 (79.8%) vs. 839/1205 (69.6%) |
| | 17/341 (5.0%) vs. 112/5081 (2.2%) | 16/341 (4.7%) vs. 46/5081 (0.9%) | 27/254 (10.6%) vs. 278/5914 (4.7%) | 5/341 (1.5%) vs. 94/5081 (1.85%) | 205/440 (46.6%) vs. 2180/6286 (34.7%) |
| OR (95% CI) | 2.55 (1.41–4.61) | 2.75 (1.38–5.45) | 1.81 (1.19–2.76) | 0.88 (0.34–2.28) | 1.68 (1.34–2.11) |
| I ² | 0% | 0% | 50% | 0% | 78% |

IADPSG, International Association of the Diabetes and Pregnancy Study Groups; CDA, Canadian Diabetes Association; NR, not reported; OR, odds ratio; CI, confidence interval.

Bold marking indicates statistically significant results.

^aFor fetal outcomes, data related to twins; ^bIncludes gestational hypertension and preeclampsia.

Table 4. Comparing of neonatal outcomes between women who were 75-g IADPSG-positive, CDA-negative (Group 3 in Table 2); vs. any controls.

| Author, (origin) (Ref) | Macrosomia | LGA | Preterm birth | NICU admission | Neonatal hypoglycemia |
|--|------------------------------------|------------------------------------|---------------------------------|---------------------------------------|---------------------------------|
| Bodmer-Roy, 2012 (Canada) (15) | 20/186 (10.8%) vs. 32/372 (8.6%) | 17/186 (9.1%) vs. 22/372 (5.9%) | 12/186 (6.5%) vs. 22/372 (5.9%) | 12/186 (6.5%) vs. 20/372 (5.4%) | 4/186 (2.2%) vs. 16/372 (4.3%) |
| Mayo, 2015 (Canada) (19) | 19/155 (12.3%) vs. 443/4709 (9.4%) | 21/155 (13.5%) vs. 389/4709 (8.2%) | NR | 11/155 (7.1%) vs. 154/4709 (3.3%) | 3/155 (1.9%) vs. 54/4709 (1.1%) |
| Tward, 2016 (Canada) ^a (21) | NR | NR | NR | 89/198 (44.9%) vs. 993/2410 (41.2%) | NR |
| Total | 39/341 (11.4%) vs. 475/5081 (9.3%) | 38/341 (11.1%) vs. 411/5081 (8.1%) | 12/186 (6.5%) vs. 22/372 (5.9%) | 112/539 (20.8%) vs. 1167/7491 (15.6%) | 7/341 (2.0%) vs. 70/5081 (1.4%) |
| OR (95% CI) | 1.32 (0.90–1.92) | 1.69 (1.15–2.48) | 1.10 (0.53–2.27) | 1.27 (0.98–1.63) | 0.79 (0.35–1.78) |
| I ² | 0% | 15% | 0% | 74% | 0% |

IADPSG, International Association of the Diabetes and Pregnancy Study Groups; CDA, Canadian Diabetes Association; NR, not reported; OR, odds ratio; CI, confidence interval; NICU, neonatal intensive care unit; LGA, large for gestational age.

Bold marking for statistically significant results.

^aFor fetal outcomes, data related to twins.

Table 5. Comparing of maternal outcomes between women who were 75-g IADPSG-positive, NICE-negative (Group 4 in Table 2); vs. any controls.

| Author, (origin) (Ref) | Preeclampsia | Polydramnios | Live birth | Intrauterine fetal death | Cesarean delivery. |
|------------------------|------------------------------------|-----------------------------------|---------------------------------------|--------------------------------|--------------------------------------|
| Meek, 2015 (UK) (20) | 39/387 (10.1%) vs. 174/2406 (7.2%) | 15/387 (3.9%) vs. 106/2406 (4.4%) | 386/387 (99.7%) vs. 2401/2406 (99.8%) | 1/387 (0.3%) vs. 5/2406 (0.2%) | 147/387 (38.0%) vs. 815/2406 (33.9%) |
| Total | 39/387 (10.1%) vs. 174/2406 (7.2%) | 15/387 (3.9%) vs. 106/2406 (4.4%) | 386/387 (99.7%) vs. 2401/2406 (99.8%) | 1/387 (0.3%) vs. 5/2406 (0.2%) | 147/387 (38.0%) vs. 815/2406 (33.9%) |
| OR (95% CI) | 1.44 (1.00–2.07) | 0.87 (0.50–1.52) | 0.80 (0.09–6.90) | 1.24 (0.14–10.68) | 1.20 (0.96–1.49) |
| I ² | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |

IADPSG, International Association of the Diabetes and Pregnancy Study Groups; NICE National Institute for Health and Care Excellence; OR, odds ratio; CI, confidence interval.

Bold marking for statistically significant results.

Table 6. Comparing of neonatal outcomes between women who were 75 g IADPSG-positive, NICE-negative (Group 4 in Table 2); vs. any controls.

| Author, (origin) (Ref) | Macrosomia | LGA | SGA | Premature delivery | NICU admission |
|------------------------|--------------------------------------|--------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Meek, 2015 (UK) (20) | 112/387 (28.9%) vs. 403/2406 (16.8%) | 115/387 (29.7%) vs. 406/2406 (16.9%) | 24/387 (6.4%) vs. 224/2406 (9.6%) | 29/387 (7.5%) vs. 127/2406 (5.3%) | 22/387 (5.7%) vs. 143/2406 (5.9%) |
| Total | 112/387 (28.9%) vs. 403/2406 (16.8%) | 115/387 (29.7%) vs. 406/2406 (16.9%) | 24/387 (6.4%) vs. 224/2406 (9.6%) | 29/387 (7.5%) vs. 127/2406 (5.3%) | 22/387 (5.7%) vs. 143/2406 (5.9%) |
| OR (95% CI) | 2.02 (1.59–2.58) | 2.08 (1.63–2.65) | 0.64 (0.42–1.00) | 1.45 (0.96–2.21) | 0.95 (0.60–1.51) |
| I ² | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |

IADPSG, International Association of the Diabetes and Pregnancy Study Groups; NICE National Institute for Health and Care Excellence; OR, odds ratio; CI, confidence interval; LGA, large for gestational age; NICU, neonatal intensive care unit; SGA, small for gestational age.

Bold marking for statistically significant results.

Table 7. Comparing of maternal outcomes between women who were 100-g IADPSG-positive, C&C-negative (Group 5 in Table 2); vs. any controls.

| Author, (origin) (Ref) | Gestational hypertension | Preeclampsia | Polydramnios | Shoulder dystocia | Cesarean delivery | Live birth | Intrauterine fetal death |
|--------------------------------|-------------------------------------|-----------------------------------|------------------------------------|-----------------------------------|--|---|-----------------------------------|
| Lapolla, 2011 (Italy) (14) | 9/112 (8.0%) vs. 76/1815 (4.2%) | NR | NR | NR | 49/112 (43.6%) vs. 564/1815 (31.1%) | NR | NR |
| Benhalima, 2013 (Belgium) (16) | 3/160 (1.9%) vs. 215/6345 (3.4%) | 1/160 (0.6%) vs. 6345 (0.6%) | NR | 6/160 (3.9%) vs. 89/6345 (1.4%) | 49/160 (30.5%) vs. 1478/6345 (23.3%) | NR | NR |
| Ethridge, 2014 (USA) (17) | 23/281 (8.2%) vs. 498/7771 (6.4%) | NR | NR | 2/281 (0.71%) vs. 65/7771 (0.84%) | 82/281 (29.2%) vs. 1818/7771 (23.4%) | NR | NR |
| Liao, 2014 (China) (18) | 40/1314 (3.0%) vs. 36/2666 (1.4%) | 26/1314 (2.0%) vs. 28/2666 (1.1%) | 8/1314 (0.61%) vs. 22/2666 (0.81%) | NR | NR | 1304/1314 (99.2%) vs. 2654/2666 (99.6%) | 10/1314 (0.8%) vs. 12/2666 (0.4%) |
| Total | 75/1867 (4.0%) vs. 825/18597 (4.4%) | 27/1474 (1.8%) vs. 66/9011 (0.7%) | 8/1314 (0.61%) vs. 22/2666 (0.81%) | 8/441 (1.8%) vs. 154/14116 (1.1%) | 180/553 (32.5%) vs. 3860/15931 (24.2%) | 1304/1314 (99.2%) vs. 2654/2666 (99.6%) | 10/1314 (0.8%) vs. 12/2666 (0.4%) |
| OR (95% CI) | 1.58 (1.21–2.07) | 1.82 (1.09–3.05) | 0.74 (0.33–1.66) | 1.76 (0.86–3.61) | 1.46 (1.21–1.75) | 0.59 (0.25–1.37) | 1.70 (0.73–3.94) |
| I ² | 15% | 0% | 0% | 0% | 0% | 0% | 0% |

IADPSG, International Association of the Diabetes and Pregnancy Study Groups; C&C Carpenter and Coustan; NR, not reported.

Bold marking for statistically significant results.

Table 8. Comparing of neonatal outcomes between women who were 100-g IADPSG-positive, C&C-negative (Group 5 in Table 2); vs. any controls.

| Author, (origin) (Ref) | Macrosomia | LGA | SGA | Preterm birth | NICU admission | Neonatal hypoglycemia |
|--------------------------------|--------------------------------------|---------------------------------------|-----------------------------------|---------------------------------------|---------------------------------------|-----------------------------------|
| Lapolla, 2011 (Italy) (14) | 12/112 (10.8%) vs. 145/1815 (8.0%) | 20/112 (18.1%) vs. 272/1815 (15.0%) | 3/112 (2.8%) vs. 58/1815 (3.2%) | NR | NR | NR |
| Benhalima, 2013 (Belgium) (16) | 14/160 (8.5%) vs. 577/6345 (9.1%) | 17/160 (10.8%) vs. 571/6345 (9.0%) | NR | 47/160 (29.2%) vs. 1643/6345 (25.9%) | 19/160 (12.0%) vs. 692/6345 (10.9%) | NR |
| Ethridge 2014 (USA) (17) | 27/281 (9.6%) vs. 371/7771 (5.0%) | 56/281 (19.9%) vs. 707/7771 (8.8%) | NR | NR | 24/281 (8.5%) vs. 520/7771 (6.7%) | NR |
| Liao, 2014 (China) (18) | 22/1314 (1.7%) vs. 60/2666 (2.3%) | 64/1314 (4.9%) vs. 138/2666 (5.2%) | 10/1314 (0.8%) vs. 48/2666 (1.8%) | 66/1314 (5.0%) vs. 156/2666 (5.9%) | 73/1314 (5.6%) vs. 106/2666 (4.0%) | 18/1314 (0.7%) vs. 18/2666 (0.7%) |
| Total | 75/1867 (4.0%) vs. 1153/18597 (6.2%) | 157/1867 (8.4%) vs. 1688/18597 (9.1%) | 13/243 (5.3%) vs. 106/4481 (2.4%) | 113/1474 (7.7%) vs. 1799/9011 (20.0%) | 116/1755 (6.6%) vs. 1318/16782 (7.9%) | 18/1314 (1.3%) vs. 18/2666 (0.7%) |
| OR (95% CI) | 1.20 (0.93–1.55) | 1.36 (1.13–1.64) | 0.49 (0.27–0.89) | 1.67 (1.33–2.10) | 1.32 (1.06–1.64) | 2.04 (1.06–3.94) |
| I ² | 38% | 74% | 0% | 87% | 35% | Not applicable |

IADPSG, International Association of the Diabetes and Pregnancy Study Groups; C&C Carpenter and Coustan; NR, not reported; OR, odds ratio; CI, confidence interval; LGA, large for gestational age; NICU, neonatal intensive care unit; SGA, small for gestational age.

Bold marking for statistically significant results.

Table 9. Comparing of maternal outcomes between study groups vs. any controls.

| Study groups (Ref) | Gestational hypertension | Preeclampsia | Hypertensive complications ^a | Polydramnios | Live birth | Intrauterine fetal death | Shoulder dystocia | Cesarean delivery |
|---|--------------------------|-------------------------|---|------------------|------------------|--------------------------|-------------------|-------------------------|
| 75-g IADPSG positive; C&A negative (Group 3 in Table 1) (15,19,21) | 2.55 (1.41–4.61) | 2.75 (1.38–5.45) | 1.81 (1.19–2.76) | NR | NR | NR | 0.88 (0.34–2.28) | 1.68 (1.34–2.11) |
| 75-g IADPSG positive; NICE negative (Group 4 in Table 1) (20) | NR | 1.44 (1.00–2.07) | NR | 0.87 (0.50–1.52) | 0.80 (0.09–6.90) | 1.24 (0.14–10.68) | NR | 1.20 (0.96–1.49) |
| 100-g IADPSG positive; C&C negative (Group 5 in Table 1) (14,16–18) | 1.58 (1.21–2.07) | 1.82 (1.09–3.05) | NR | 0.74 (0.33–1.66) | 0.59 (0.25–1.37) | 1.70 (0.73–3.94) | 1.76 (0.86–3.61) | 1.46 (1.21–1.75) |

IADPSG, International Association of Diabetes Pregnancy Study Group; C&A, Canadian Diabetes Association; NICE, National Institute for Health and Care Excellence; C&C, Carpenter and Coustan; NR, not reported.

Bold marking for statistically significant results.

^aIncludes gestational hypertension and preeclampsia.

Table 10. Comparing of neonatal outcomes between study groups vs. any controls.

| Study groups | Macrosomia | LGA | SGA | Preterm birth | NICU admission | Neonatal hypoglycemia |
|---|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| 75-g IADPSG positive; CDA negative (Group 3 in Table 1) (15,19,21) | 1.32 (0.90–1.92) | 1.69 (1.15–2.48) | NR | 1.10 (0.53–2.27) | 1.27 (0.98–1.63) | 0.79 (0.35–1.78) |
| 75-g IADPSG positive; NICE negative (Group 4 in Table 1) (20) | 2.02 (1.59–2.58) | 2.08 (1.63–2.65) | 0.64 (0.42–1.00) | 1.45 (0.96–2.21) | 0.95 (0.60–1.51) | NR |
| 100-g IADPSG positive; C&C negative (Group 5 in Table 1) (14,16–18) | 1.20 (0.93–1.55) | 1.36 (1.13–1.64) | 0.49 (0.27–0.89) | 1.67 (1.33–2.10) | 1.32 (1.06–1.64) | 2.04 (1.06–3.94) |

IADPSG, International Association of Diabetes Pregnancy Study Group; CDA, Canadian Diabetes Association; NICE, National Institute for Health and Care Excellence; C&C, Carpenter and Coustan criteria; LGA, large for gestational age; SGA, small for gestational age; NICU, neonatal intensive care unit; NR, not reported. Bold marking indicates statistically significant results.

106/4481 (2.4%); OR 0.49, 95% CI 0.27–0.89] were significantly less common. Our main outcome, macrosomia, was more frequent in women positive at 100-g IADPSG criteria and C&C-criteria negative, but did not reach a statistically significant difference [75/1867 (4.0%) vs. 1153/18597 (6.2%); OR 1.20, 95% CI 0.93–1.55] (Table 7 and 8).

We identified no study that evaluated whether treatment of women meeting criteria for GDM by IADPSG criteria but not by other less strict criteria has an effect on adverse pregnancy outcomes compared with no treatment.

Discussion

This meta-analysis showed that women meeting criteria for GDM by IADPSG criteria but not by other less strict criteria have an increased risk of adverse pregnancy outcomes such as gestational hypertension, preeclampsia and LGA, compared with GDM-negative controls. These findings are limited by the risk of bias of the included studies and by the high heterogeneity within the studies.

When analyzing outcomes of all study groups with respect to all control groups for maternal outcomes, we found that gestational hypertension and preeclampsia were consistently significantly more common in women who were GDM positive by more strict IADPSG criteria compared with GDM-negative controls, and cesarean delivery was also more common, with two of three analyses being statistically significant (Table 9). When analyzing outcomes of all study groups with respect to all control groups for neonatal outcomes, we found that LGA was consistently significantly more common in women who were GDM positive by more strict IADPSG criteria compared with GDM-negative controls, and macrosomia and preterm birth were also more common, with only one of the analyses being statistically significant; SGA was less common in the two available analyses, with one of these being statistically significant (Table 10).

Despite continuing controversy over whether the One Step test or the Two Step tests should be used for GDM screening, we identified no study that evaluated if treatment of women meeting criteria for GDM by IADPSG criteria (One Step test) but not by other less strict criteria has an effect on adverse pregnancy outcomes compared with no treatment. Moreover, none of the included studies treated for GDM the study group with milder disease (positive for IADPSG criteria, but negative for less stringent criteria).

We are not aware of such a comprehensive systematic review on maternal and neonatal outcomes in women meeting criteria for GDM by IADPSG criteria but not by other less strict criteria compared with GDM-

negative controls. The first issue in deciding whether to use the One Step or the Two Step for GDM screening and diagnosis is to ascertain if women diagnosed with the One Step, but not the Two Step, are at increased risk for complications compared with GDM-negative controls. The fact that for the first time a comprehensive review finds that gestational hypertension, preeclampsia and LGA, as well as possibly cesarean delivery, macrosomia and preterm birth, are more frequent, and SGA possibly less frequent, in women diagnosed with GDM by the One Step, but not the Two Step, is an important strength of our study. Moreover, none of the studies treated women identified with the One Step, but not the Two Step, so the results are not affected by GDM therapy.

There are also several limitations to our study. In each study group we identified only a few studies, and, importantly, no one was a randomized controlled trial (RCT). We also found a large variety of different criteria (IADPSG, WHO, NICE, CDA, C&C) for screening for GDM used in the literature, as can be seen in the Supplementary material (Table S1). Moreover, some studies used 75-g (IADPSG) criteria in women who instead had the 100-g glucose load. Furthermore, in study group 5 [women who had at least one positive value on the 100-g OGTT according to IADPSG criteria, but were negative by C&C criteria at the 100-g OGTT test (100-g IADPSG-positive; C&C-negative)] the authors applied IADPSG criteria in women who underwent 100-g OGTT rather than 75-g OGTT.

To compare the One Step test to the Two Step tests for GDM screening and diagnosis, several possible study designs have been evaluated in the literature.

Only one RCT has been published in which women underwent both the One Step and the Two Step test. Weiss et al. concluded that, although in metabolically healthy women both different GDM screening approaches lead to statistically different blood glucose levels at 1 and 2 h, in GDM 1-h glucose levels do not differ after a 75-g or 100-g load, and this is due to elevated insulin resistance shown by a low insulin/glucose quotient at 1 h. For comparison of tests in GDM only, 2-h values must be adjusted by 16 mg/dL after different loading (22).

Three RCTs comparing the One Step with the Two Step approaches have been published (7,8,23–28). The meta-analysis of the three RCTs included 2,333 women. No significant difference in the incidence of GDM was found comparing the One Step vs. the Two Step approaches (8.4% vs. 4.3%; RR 1.64, 95% CI 0.77 to 3.48). Women screened with the One Step approach had a significantly lower risk of preterm birth (PTB) (3.7% vs. 7.6%; RR 0.49, 95% CI 0.27 to 0.88), cesarean delivery (16.3% vs. 22.0%; RR 0.74, 95% CI 0.56 to 0.99),

macrosomia (2.9% vs. 6.9%; RR 0.43, 95% CI 0.22 to 0.82), neonatal hypoglycemia (1.7% vs. 4.5%; RR 0.38, 95% CI 0.16 to 0.90), and admission to neonatal intensive care unit (NICU) (4.4% vs. 9.0%; RR 0.49, 95% CI 0.29 to 0.84), compared to those randomized to screening with the Two Step approach (29).

Several prospective non-RCTs or retrospective studies comparing the incidence of GDM and/or outcomes between the One Step and Two Step methods have also been published (30–37). Polled data of these studies show that GDM-positive women at One Step test, when treated, have better maternal and neonatal outcomes, compared with treated women GDM positive at Two Step test.

In summary, compared with GDM-negative women, women positive at the One Step test by IADPSG criteria but negative at the Two Step test are at increased risk for gestational hypertension, preeclampsia and LGA, as well as possibly cesarean delivery, macrosomia and preterm birth, while possibly being at decreased risk for SGA. Given the fact that the One Step approach has been often associated in RCTs (7,8,28,38,39) with better maternal and perinatal outcomes, including lower risk of preterm birth, cesarean delivery, macrosomia, neonatal hypoglycemia, admission to NICU and lower mean birthweight, compared with the Two Step approach, consideration should be given to universal adoption of the One Step approach using the IADPSG criteria for GDM screening and diagnosis.

Funding

No financial support was received for this study.

References

1. American Diabetes Association. Classification and diagnosis of diabetes. *Diabetes Care*. 2017;40(Suppl):1.
2. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care*. 2010;33:676–82.
3. WHO 2013. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Available online at: http://apps.who.int/iris/bitstream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf (accessed November 25, 2017).
4. Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis,

- management, and care. *Int J Gynaecol Obstet.* 2015;131 (Suppl 3):S173–211.
5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Thompson D, Berger H, Feig D, Gagnon R, Kader T, et al. Diabetes and Pregnancy. *Can J Diabetes.* 2013;37(Suppl 1):S168–83.
 6. Committee on Practice. Bulletins—Obstetrics. Gestational diabetes mellitus. Practice Bulletin No. 137. American College of Obstetricians and Gynecologists. *Obstet Gynecol.* 2013;122:406–16.
 7. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. *Engl J Med.* 2008;358:1991–2002.
 8. Sevet O, Ates S, Uysal O, Molla T, Dansuk R, Kelekci S. To evaluate the prevalence and clinical outcomes using a one-step method versus a two-step method to screen gestational diabetes mellitus. *J Matern Fetal Neonatal Med.* 2014;27:36–41.
 9. WHO Definition, diagnosis and classification of Diabetes Mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. 1999. Available online at: http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf (accessed May 1, 2017).
 10. NICE Guideline. Diabetes in pregnancy: management from preconception to the postnatal period. February 2015. Available online at: <https://www.nice.org.uk/guidance/ng3/> (accessed May 1, 2017).
 11. Deerochanawong C, Putiyanun C, Wongsuryrat M, Serirat S, Jinayon P. Comparison of National Diabetes Data Group and World Health Organization criteria for detecting gestational diabetes mellitus. *Diabetologia.* 1996;39:1070–3.
 12. Mello G, Parretti E, Ognibene A, Cioni R, Tondi F, Pezzati P, et al. Lack of concordance between the 75-g and 100-g glucose load tests for the diagnosis of gestational diabetes mellitus. *Clin Chem.* 2006;52:1679–84.
 13. O'Sullivan EP, Avalos G, O'Reilly M, Dennedy MC, Gaffney G, Dunne F, et al. Atlantic Diabetes in Pregnancy (DIP): the prevalence and outcomes of gestational diabetes mellitus using new diagnostic criteria. *Diabetologia.* 2011;54:1670–5.
 14. Lapolla A, Dalfrà MG, Ragazzi E, De Cata AP, Fedele D. New International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations for diagnosing gestational diabetes compared with former criteria: a retrospective study on pregnancy outcome. *Diabet Med.* 2011;28:1074–7.
 15. Bodmer-Roy S, Morin L, Cousineau J, Rey E. Pregnancy outcomes in women with and without gestational diabetes mellitus according to the International Association of the Diabetes and Pregnancy Study Groups criteria. *Obstet Gynecol.* 2012;120:746–52.
 16. Benhalima K, Hanssens M, Devlieger R, Verhaeghe J, Mathieu C. Analysis of pregnancy outcomes using the new IADPSG recommendation compared with the carpenter and coustan criteria in an area with a low prevalence of gestational diabetes. *Int J Endocrinol.* 2013;2013:248121.
 17. Ethridge JK Jr, Catalano PM, Waters TP. Perinatal outcomes associated with the diagnosis of gestational diabetes made by the international association of the diabetes and pregnancy study groups criteria. *Obstet Gynecol.* 2014;124:571–8.
 18. Liao S, Mei J, Song W, Liu Y, Tan Y-D, Chi S, et al. The impact of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) fasting glucose diagnostic criterion on the prevalence and outcomes of gestational diabetes mellitus in Han Chinese women. *Diabet Med.* 2014;31:341–51.
 19. Mayo K, Melamed N, Vandenbergh H, Berger H. The impact of adoption of the international association of diabetes in pregnancy study group criteria for the screening and diagnosis of gestational diabetes. *Am J Obstet Gynecol.* 2015;212:224.
 20. Meek CL, Lewis HB, Patient C, Murphy HR, Simmons D. Diagnosis of gestational diabetes mellitus: falling through the net. *Diabetologia.* 2015;58:2003–12.
 21. Tward C, Barrett J, Berger H, Kibel M, Pittini A, Halperin I, et al. Does gestational diabetes affect fetal growth and pregnancy outcome in twin pregnancies? *Am J Obstet Gynecol.* 2016;214:653.
 22. Weiss PA, Haeusler M, Kainer F, Pürstner P, Haas J. Toward universal criteria for gestational diabetes: relationships between seventy-five and one hundred gram glucose loads and between capillary and venous glucose concentrations. *Am J Obstet Gynecol.* 1998;178:830–5.
 23. Coustan DR, Lewis SB. Insulin therapy for gestational diabetes. *Obstet Gynecol.* 1978;51:306–10.
 24. Thompson DJ, Porter KB, Gunnells DJ, Wagner PC, Spinnato JA. Prophylactic insulin in the management of gestational diabetes. *Obstet Gynecol.* 1990;75:960–4.
 25. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *N Engl J Med.* 2005;352:2477–86.
 26. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. *N Engl J Med.* 2009;361:1339–48.
 27. Casey BM, Duryea EL, Abbassi-Ghanavati M, Tudela CM, Shivvers SA, McIntire DD, et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. *Obstet Gynecol.* 2015;126:303–9.
 28. Meltzer SJ, Snyder J, Penrod JR, Nudi M, Morin L. Gestational diabetes mellitus screening and diagnosis: a prospective randomised controlled trial comparing costs of one-step and two-step methods. *BJOG.* 2010;117:407–15.
 29. Saccone G, Caissutti C, Khalifeh A, Meltzer S, Scifres C, Simhan HN, et al. One Step versus Two Step approach for gestational diabetes screening: systematic review and meta-analysis of the randomized trials. *J Matern Fetal Neonatal*

- Med. 2017;1–211 [Epub ahead of print]. <https://doi.org/10.1080/14767058.2017.1408068>.
30. Duran A. Introduction of IADPSG criteria for the screening and diagnosis of gestational diabetes mellitus results in improved pregnancy outcomes at a lower cost in a large cohort of pregnant women: The St. Carlos Gestational Diabetes Study. *Diabetes Care*. 2014;37:2442–50.
 31. Fuller KP, Borgida AF. Gestational diabetes mellitus screening using the one-step versus two-step method in a high-risk practice. *Clin Diabetes*. 2014;32:148–50.
 32. Liu X, Chen Y, Zhou Q, Shi H, Cheng WW. Utilization of International Association of Diabetes and Pregnancy Study Groups criteria vs. a two-step approach to screening for gestational diabetes mellitus in Chinese women with twin pregnancies. *Diabet Med*. 2015;32:367–73.
 33. Oriot P, Selvais P, Radikov J, Jacobs JL, Gillemann U, Loumaye R, et al. Assessing the incidence of gestational diabetes and neonatal outcomes using the IADPSG guidelines in comparison with the Carpenter and Coustan criteria in a Belgian general hospital. *Acta Clin Belg*. 2014;69:8–11.
 34. Wei YM, Yang HX, Zhu WW, Yang HY, Li HX, Kapur A. Effects of intervention to mild GDM on outcomes. *J Matern Fetal Neonatal Med*. 2015;28:928–31.
 35. Hung T-H, Hsieh T-T. The effects of implementing the international association of diabetes and pregnancy study groups criteria for diagnosing gestational diabetes on maternal and neonatal outcomes. *PLoS ONE*. 2015;10: e0122261.
 36. Kong JM, Lim K, Thompson DM. Evaluation of the International Association of the Diabetes In Pregnancy Study Group new criteria: gestational diabetes project. *Can J Diabetes*. 2015;39:128–32.
 37. Assaf-Balut C, Bordiú E, Del Valle L, Lara M, Duran A, Rubio MA, et al. The impact of switching to the one-step method for GDM diagnosis on the rates of postpartum screening attendance and glucose disorder in women with prior GDM. The San Carlos Gestational Study. *J Diabetes Complications*. 2016;30:1360–4.
 38. Feldman RK, Tieu RS, Yasumura L. Gestational diabetes screening: the International Association of the Diabetes and Pregnancy Study Groups compared with Carpenter-Coustan screening. *Obstet Gynecol*. 2016;127:10–7.
 39. American Diabetes Association. 2. Classification and diagnosis of diabetes. *Diabetes Care*. 2015;38(Suppl 1):S8–16.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Table S1. Criteria for gestational diabetes mellitus diagnosis.